Tyra Biosciences (TYRA) EBIT (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of EBIT data on file, last reported at -$42.0 million in Q1 2026.

• Quarterly EBIT fell 31.86% year-over-year to -$42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$142.9 million (down 25.66% YoY) and the FY2025 annual result came in at -$132.8 million, down 27.44% from the prior year.
• EBIT declined to -$42.0 million in Q1 2026, from -$36.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$13.6 million in Q3 2022 to a low of -$42.0 million in Q1 2026.
• A 5-year average of -$24.6 million and a median of -$24.0 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT plunged 252.27% — and 2023, when it increased 3.37%.
• Tracing TYRA's EBIT over 5 years: stood at -$15.0 million in 2022, then plunged by 70.69% to -$25.6 million in 2023, then decreased by 16.03% to -$29.7 million in 2024, then declined by 22.77% to -$36.5 million in 2025, then slipped by 15.01% to -$42.0 million in 2026.
• The last three EBIT figures came in at -$42.0 million (Q1 2026), -$36.5 million (Q4 2025), and -$32.9 million (Q3 2025), per Business Quant data.